(Q46908044)

English

Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities

scientific article published in February 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16432276

Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities (English)

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16432276

1 reference

based on heuristic

inferred from title

author name string

Keith Tan

1

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16432276

Nigel Brayshaw

2

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16432276

Konrad Tomaszewski

3

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16432276

Peter Troke

4

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16432276

Nolan Wood

5

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16432276

publication date

1 February 2006

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16432276

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16432276

46

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16432276

2

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16432276

235-243

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16432276

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283837

21 January 2018

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283837

21 January 2018

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283837

21 January 2018

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283837

21 January 2018

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283837

21 January 2018

Newer systemic antifungal agents : pharmacokinetics, safety and efficacy

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283837

21 January 2018

Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283837

21 January 2018

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283837

21 January 2018

The safety of voriconazole

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283837

21 January 2018

Safety of voriconazole and dose individualization

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283837

21 January 2018

The pharmacokinetics and safety of intravenous voriconazole – a novel wide‐spectrum antifungal agent

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283837

21 January 2018

Voriconazole, a novel wide‐spectrum triazole: oral pharmacokinetics and safety

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283837

21 January 2018

The meaning and use of the area under a receiver operating characteristic (ROC) curve

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283837

21 January 2018

Treatment of systemic fungal infections in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283837

21 January 2018

Identifiers

10.1177/0091270005283837

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16432276

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16432276

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46908044&oldid=2137479359"